The Role of Complement C3 and C5a in Hyperinflammation, Cytokine Storm, and Immune Dysregulation during Severe COVID-19 Infection
DOI:
https://doi.org/10.70749/ijbr.v3i4.1163Keywords:
COVID-19, Cytokine, Complement system, and HyperinflammationAbstract
Severe COVID-19 is characterized by an excessive inflammatory response, often leading to acute respiratory distress syndrome (ARDS), multi-organ dysfunction, and high mortality. The complement system, particularly components C3 and C5a, has emerged as a critical driver of hyper inflammation and immune dysregulation in severe cases. This study aimed to investigate the roles of C3 and C5a in relation to disease severity, inflammatory markers, cytokine profiles, and clinical outcomes in hospitalized COVID-19 patients. A prospective observational study was conducted involving 150 participants: 60 with severe COVID-19, 60 with moderate disease, and 30 healthy controls. Plasma levels of C3 and C5a were measured using ELISA, while cytokines (IL-6, TNF-α, IL-1β, IFN-γ) were quantified via multiplex immunoassays. Additional clinical parameters, including CRP, ferritin, and hospital stay duration, and need for mechanical ventilation, were recorded. Correlation analyses were performed to explore associations between complement activity and disease outcomes. Both C3 and C5a levels were significantly elevated in severe COVID-19 patients compared to moderate cases and controls (p < 0.001). C5a showed strong positive correlations with IL-6 (r = 0.78) and hospital stay duration (r = 0.59). Patients with high C5a levels had longer hospitalizations and were more likely to require mechanical ventilation. Elevated complement levels also correlated with increased CRP, ferritin, and SOFA scores. Complement over activation, particularly C5a, is strongly associated with hyperinflammation, immune dysregulation, and poor outcomes in severe COVID-19. Targeting the complement cascade may offer a promising therapeutic strategy and aid in clinical risk stratification.
Downloads
References
Alosaimi, B., Mubarak, A., Hamed, M. E., Almutairi, A. Z., Alrashed, A. A., AlJuryyan, A., Alturaiki, W. (2021). Complement anaphylatoxins and inflammatory cytokines as prognostic markers for COVID-19 severity and in-hospital mortality. Frontiers in immunology, 12, 668725. https://doi.org/10.3389/fimmu.2021.668725
Avdonin, P. P., Blinova, M. S., Serkova, A. A., Komleva, L. A., & Avdonin, P. V. (2024). Immunity and Coagulation in COVID-19. International Journal of Molecular Sciences, 25(20), 11267. https://doi.org/10.3390/ijms252011267
Aziz, N., Mehmood, A., Jadoon, A., Farooq, H., Tariq, M. U., Gul, M., . . . Tahir, H. (2021). Gut Microbiome Association with Chronic Inflammations in COVID-19 Patients. Annals of the Romanian Society for Cell Biology, 25(7).
Buchanan, D. (2021). Dysregulation, Deficiency, and Virus Associated Pathologies Related to the Complement System. The University of Arizona.
Carvelli, J., Demaria, O., Vély, F., Batista, L., Chouaki Benmansour, N., Fares, J., . . . Remark, R. (2020). Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature, 588(7836), 146-150. https://doi.org/10.1136/jitc-2020-sitc2020.0483
Chauhan, A. J., Wiffen, L. J., & Brown, T. P. (2020). COVID‐19: a collision of complement, coagulation and inflammatory pathways. Journal of Thrombosis and Haemostasis, 18(9), 2110-2117. https://doi.org/10.1111/jth.14981
Cyprian, F. S., Suleman, M., Abdelhafez, I., Doudin, A., Masud Danjuma, I. M., Mir, F. A., . . . Abdelmajid, A. (2021). Complement C5a and clinical markers as predictors of COVID-19 disease severity and mortality in a multi-ethnic population. Frontiers in Immunology, 12, 707159. https://doi.org/10.3389/fimmu.2021.707159
David, M., & Naicker, T. (2023). The complement system in preeclampsia: a review of its activation and endothelial injury in the triad of COVID-19 infection and HIV-associated preeclampsia. Obstetrics & Gynecology Science, 66(4), 253-269. https://doi.org/10.5468/ogs.22175
Fodil, S., & Annane, D. (2021). Complement inhibition and COVID-19: the story so far. ImmunoTargets and Therapy, 273-284. https://doi.org/10.2147/itt.s284830
Gianni, P., Goldin, M., Ngu, S., Zafeiropoulos, S., Geropoulos, G., & Giannis, D. (2022). Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review. World Journal of Experimental Medicine, 12(4), 53. https://doi.org/10.5493/wjem.v12.i4.53
Jodele, S., & Köhl, J. (2021). Tackling COVID‐19 infection through complement‐targeted immunotherapy. British Journal of Pharmacology, 178(14), 2832-2848. https://doi.org/10.1111/bph.15187
Laudanski, K., Okeke, T., Siddiq, K., Hajj, J., Restrepo, M., Gullipalli, D., & Song, W.-c. (2022). A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce. Scientific Reports, 12(1), 13658. https://doi.org/10.1038/s41598-022-17011-7
Leatherdale, A., Stukas, S., Lei, V., West, H. E., Campbell, C. J., Hoiland, R. L., . . . Pryzdial, E. L. (2022). Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality. Medical microbiology and immunology, 1-12. https://doi.org/10.1007/s00430-021-00725-2
Li, J., & Liu, B. (2021). The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine & growth factor reviews, 58, 75-81. https://doi.org/10.1016/j.cytogfr.2020.12.001
Lipcsey, M., Persson, B., Eriksson, O., Blom, A. M., Fromell, K., Hultström, M., . . . Nilsson, B. (2021). The outcome of critically ill COVID-19 patients is linked to thromboinflammation dominated by the kallikrein/kinin system. Frontiers in immunology, 12, 627579. https://doi.org/10.3389/fimmu.2021.627579
Mastellos, D. C., da Silva, B. G. P., Fonseca, B. A., Fonseca, N. P., Auxiliadora-Martins, M., Mastaglio, S., . . . Chrysanthopoulou, A. (2020). Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology, 220, 108598. https://doi.org/10.1016/j.clim.2020.108598
Murad, D., Paracha, R. Z., Saeed, M. T., Ahmad, J., Mushtaq, A., & Humayun, M. (2023). Modelling and analysis of the complement system signalling pathways: roles of C3, C5a and pro-inflammatory cytokines in SARS-CoV-2 infection. PeerJ, 11, e15794. https://doi.org/10.7717/peerj.15794
Ostrycharz, E., & Hukowska-Szematowicz, B. (2022). New insights into the role of the complement system in human viral diseases. Biomolecules, 12(2), 226. https://doi.org/10.3390/biom12020226
Pires, B. G., & Calado, R. T. (2023). Hyper‐inflammation and complement in COVID‐19. American Journal of Hematology, 98, S74-S81. https://doi.org/10.1002/ajh.26746
Satyam, A., & Tsokos, G. C. (2020). Curb complement to cure COVID-19. Clinical Immunology (Orlando, Fla.), 221, 108603. https://doi.org/10.1016/j.clim.2020.108603
Torabizadeh, M., Modaresi Asfeh, H., Deris Zayeri, Z., Dominique, C., Kazemi, H., & Saki, N. (2023). Implications of complement imbalance in COVID-19: a molecular mechanistic discussion on the importance of complement balance. Iranian Journal of Immunology, 20(3), 247-261.
Yu, J., Gerber, G. F., Chen, H., Yuan, X., Chaturvedi, S., Braunstein, E. M., & Brodsky, R. A. (2021). Complement dysregulation is associated with severe COVID-19 illness. Haematologica, 107(5), 1095. https://doi.org/10.3324/haematol.2021.279155
Zinellu, A., & Mangoni, A. A. (2021). Serum complement C3 and C4 and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression. Frontiers in immunology, 12, 696085. https://doi.org/10.3389/fimmu.2021.696085
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
